Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Lippman

Showing results (41-50 of 340) with videos related to

Pageof 34
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2024
Reply to: Optimizing DeepHRD Interpretability for Enhanced Clinical Decision MakingErik N Bergstrom, Scott M Lippman, Ludmil B Alexandrov
Expert Opinion on Therapeutic Targets|January 14, 2012
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapyLibero Santarpia, Scott M Lippman, Adel K El-Naggar
Topics in Current Chemistry|August 2, 2012
Natural-agent mechanisms and early-phase clinical developmentJanet L Wang, Kathryn A Gold, Scott M Lippman
Journal of the National Cancer Institute|April 10, 2016
The Conundrum of Genetic "Drivers" in Benign ConditionsShumei Kato, Scott M Lippman, Keith T Flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathwaysScott M Lippman, Neil Gibson, Kotha Subbaramaiah, et al.
Molecular Cancer Therapeutics|November 9, 2005
The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cellsLinda C Hsi, Xiaopei Xi, Yuanqing Wu, et al.
Genome Medicine|February 19, 2020
The paradox of cancer genes in non-malignant conditions: implications for precision medicineJacob J Adashek, Shumei Kato, Scott M Lippman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2019
Targeting mTOR in Head and Neck Cancer-ResponseJ Silvio Gutkind, Terry A Day, Scott M Lippman, et al.
Head & Neck|July 16, 2013
Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatmentGerald S Falchook, Scott M Lippman, Christel C Bastida, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 23, 2020
Effects of curative-intent lung cancer therapy on functional exercise capacity and patient-reported outcomesDuc Ha, Andrew L Ries, Scott M Lippman, et al.
Pageof 34

Showing results (41-50 of 340) with videos related to

Sort By:
Pageof 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2024
Reply to: Optimizing DeepHRD Interpretability for Enhanced Clinical Decision MakingErik N Bergstrom, Scott M Lippman, Ludmil B Alexandrov
Expert Opinion on Therapeutic Targets|January 14, 2012
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapyLibero Santarpia, Scott M Lippman, Adel K El-Naggar
Topics in Current Chemistry|August 2, 2012
Natural-agent mechanisms and early-phase clinical developmentJanet L Wang, Kathryn A Gold, Scott M Lippman
Journal of the National Cancer Institute|April 10, 2016
The Conundrum of Genetic "Drivers" in Benign ConditionsShumei Kato, Scott M Lippman, Keith T Flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathwaysScott M Lippman, Neil Gibson, Kotha Subbaramaiah, et al.
Molecular Cancer Therapeutics|November 9, 2005
The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cellsLinda C Hsi, Xiaopei Xi, Yuanqing Wu, et al.
Genome Medicine|February 19, 2020
The paradox of cancer genes in non-malignant conditions: implications for precision medicineJacob J Adashek, Shumei Kato, Scott M Lippman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2019
Targeting mTOR in Head and Neck Cancer-ResponseJ Silvio Gutkind, Terry A Day, Scott M Lippman, et al.
Head & Neck|July 16, 2013
Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatmentGerald S Falchook, Scott M Lippman, Christel C Bastida, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 23, 2020
Effects of curative-intent lung cancer therapy on functional exercise capacity and patient-reported outcomesDuc Ha, Andrew L Ries, Scott M Lippman, et al.
Pageof 34